New Survey by Greystone Associates Analyzes Therapeutic and Market Factors
(Amherst, NH) – Interest in nasal sprays for systemic drug delivery has increased dramatically in the last five years, driven by the need to develop new alternatives to oral delivery for protein and peptide-based drugs, and the belief that intranasal drug delivery may lead to greater drug efficacy, speed of action, safety, and patient compliance. Systemic intranasal drug delivery leverages the patient-friendly and favorable pharmacodynamics and pharmacoeconomics of intranasal administration to deliver drugs systemically. Nasal delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs.
As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patient-friendly and cost-effective. Intranasal administration is well positioned to take advantage of these trends and evolve into a significant role in the future of pharmaceutical development and commercialization.
There are currently more than two-dozen companies actively pursuing intranasal drug delivery products. These companies believe the advantages of nasal drug delivery provide significant market opportunities, particularly against oral and injectable therapy. Systemic nasal sprays will grow at the expense of the predominant drug delivery methods which cannot be readily optimized for the delivery and dosing of a significant portion of biologically derived drug substances.
Systemic Nasal Sprays: Markets & Opportunities, a recently released report, analyzes existing and emerging systemic nasal spray products, market participants, and key demand and technology factors influencing the commercial market and shaping growth in this sector. It is available from Greystone Associates by visiting
http://www.greystoneassociates.org/Intranasal.htm
More information is also available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
Comment and add to the story without registration, but keep the comments meaningful please. Links are not accepted.
